How did the Neuro and Spine Associates acquisition change the financials?

Consolidating the 60% stake added enough revenue to nearly triple the top line to ₹94.2 cr. Its costs flipped the group to a net loss of ₹4.75 cr.

What happened to standalone profit?

Standalone net profit fell 84% to ₹26.5 lakh from ₹166.4 lakh, even as revenue more than doubled to ₹67.5 cr. The decline is independent of the acquisition.

Did the auditor flag any issues?

No. The statutory auditor issued an unmodified opinion on both sets of statements, confirming the figures are presented fairly.

Is the core business profitable?

The standalone business is profitable, but just barely. It generated ₹26.5 lakh in profit on ₹67.5 cr in revenue, a margin under 0.04%.

Earnings · Trading · Micro cap

Eyantra's revenue tripled. Its new healthcare unit posted a ₹4.75 cr loss.

Consolidating a 60% stake in Neuro and Spine Associates flipped the group to a net loss, even as standalone profit fell 84%.

— 1 earlier story on Eyantra ventures Ltd. →

EY By Tipsheet Editorial 25 May 2026 · 7:35 PM IST Verify on BSE · NSE

Mkt cap₹131 cr

ROE2.69%

Debt / eq.0.00

₹4.75 cr Consolidated net loss after acquiring Neuro and Spine Associates.

What's new

Consolidated revenue nearly tripled to ₹94.2 cr, driven by the consolidation of a 60% stake in Neuro and Spine Associates.
The group posted a net loss of ₹4.75 cr, while standalone net profit fell 84% to ₹26.5 lakh.
The statutory auditor gave an unmodified opinion on both standalone and consolidated financial statements.

Why this matters

The healthcare acquisition delivered revenue but destroyed profitability. Standalone profit was already falling before consolidation. The clean audit opinion confirms the numbers, but not the wisdom of the deal.

What we're watching

Whether Neuro and Spine Associates can turn profitable to stop dragging the group down.
Next quarter's standalone profit trend to gauge core business health.
Any further capital allocation to the healthcare vertical.

The full read

Eyantra's growth is an acquisition. Consolidating Neuro and Spine Associates drove group revenue to ₹94.2 crore. It also drove the group to a ₹4.75 crore loss. Standalone, the picture was already deteriorating. Revenue more than doubled to ₹67.5 crore, but profit cratered 84% to ₹26.5 lakh. The margin on that standalone revenue is negligible. The clean auditor's opinion means the numbers are real. The open question is whether the healthcare stake can deliver returns. So far, it has delivered only scale.

Questions answered

How did the Neuro and Spine Associates acquisition change the financials?: Consolidating the 60% stake added enough revenue to nearly triple the top line to ₹94.2 cr. Its costs flipped the group to a net loss of ₹4.75 cr.
What happened to standalone profit?: Standalone net profit fell 84% to ₹26.5 lakh from ₹166.4 lakh, even as revenue more than doubled to ₹67.5 cr. The decline is independent of the acquisition.
Did the auditor flag any issues?: No. The statutory auditor issued an unmodified opinion on both sets of statements, confirming the figures are presented fairly.
Is the core business profitable?: The standalone business is profitable, but just barely. It generated ₹26.5 lakh in profit on ₹67.5 cr in revenue, a margin under 0.04%.

Mentioned: Neuro and Spine Associates (60% stake) · ₹94.2 cr consolidated revenue · ₹4.75 cr net loss

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on EY →

25 May 2026 · 7:35 PM IST Eyantra's revenue tripled. Its new healthcare unit posted a ₹4.75 cr loss.
42d ago Eyantra's revenue tripled after hospital deal, but full-year profit vanished